Chronic obstructive pulmonary disease. Mortality and mortality reduction

Area of Science:

• Pulmonology
• Public Health

Background:

• Chronic obstructive pulmonary disease (COPD) impacts millions globally and is a leading cause of death.
• Current COPD treatments have seen minimal advancement over decades, despite increased disease understanding.
• Smoking is the primary risk factor, responsible for approximately 90% of COPD cases.

Purpose of the Study:

• To review the current landscape of COPD management.
• To emphasize the critical role of smoking cessation in COPD intervention.
• To discuss the limitations of existing and emerging pharmacotherapeutic options.

Main Methods:

• Literature review of COPD epidemiology, risk factors, and treatment modalities.
• Analysis of the efficacy of current pharmacotherapies and recent investigational agents.
• Evaluation of the significance of smoking cessation as a primary intervention.

Main Results:

• Smoking cessation remains the most effective intervention for managing COPD.
• Pharmacotherapeutic options like corticosteroids, bronchodilators, and antibiotics address symptoms and exacerbations but do not alter disease progression significantly.
• Investigational treatments, such as dornase alfa for exacerbations, have shown disappointing results without mortality benefits.

Conclusions:

• Smoking cessation is paramount for controlling COPD and should be the focus of public health initiatives.
• While research continues to explore new treatments, optimizing existing therapies and reinforcing smoking cessation are key.
• Effective COPD management hinges on addressing the root cause—smoking—and supporting cessation efforts.